Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Xenon Pharmaceuticals Inc.XENE · Entity 2602 | Chief Financial Officer | December 18, 2024 | December 19, 2024 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Xenon Pharmaceuticals Inc.
Report date December 18, 2024 · Filed December 19, 2024
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common SharesSEC Table I · non-derivative | Direct | 0 |
Ending reported balance
After 2024-12-18 transaction · row 6
6 source rows · reconciled sequenceRow 1 · 2024-12-18 · Exercise / conversion · Acquired 9,334 · Balance 9,334 Row 2 · 2024-12-18 · Tax withholding · Disposed 2,135 · Balance 7,199 F1: Represents the closing price of the Company's common shares on December 17, 2024 for purposes of net settlement calculations. Row 3 · 2024-12-18 · Sale · Disposed 7,199 · Balance 0 Row 4 · 2024-12-18 · Exercise / conversion · Acquired 16,000 · Balance 16,000 Row 5 · 2024-12-18 · Tax withholding · Disposed 4,490 · Balance 11,510 F1: Represents the closing price of the Company's common shares on December 17, 2024 for purposes of net settlement calculations. Row 6 · 2024-12-18 · Sale · Disposed 11,510 · Balance 0 F2: The "Amount" and "Price" reported in this Column 4 reflect the aggregate number and weighted-average price, respectively, of shares sold. These shares were sold in multiple transactions at prices ranging from $41.19 to $41.20, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, full information regarding the number of shares sold at each separate price within the range set forth herein. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $9.44 · Expires 2029-09-15 | Direct | 0 |
Reported balance
After 2024-12-18 transaction · row 7
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 7 · 2024-12-18 · Exercise / conversion · Disposed 9,334 · Balance 0 F3: The shares subject to the option are fully vested and exercisable. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $11.58 · Expires 2030-03-11 | Direct | 6,000 |
Reported balance
After 2024-12-18 transaction · row 8
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 8 · 2024-12-18 · Exercise / conversion · Disposed 16,000 · Balance 6,000 F3: The shares subject to the option are fully vested and exercisable. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents the closing price of the Company's common shares on December 17, 2024 for purposes of net settlement calculations.
F2: The "Amount" and "Price" reported in this Column 4 reflect the aggregate number and weighted-average price, respectively, of shares sold. These shares were sold in multiple transactions at prices ranging from $41.19 to $41.20, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, full information regarding the number of shares sold at each separate price within the range set forth herein.
F3: The shares subject to the option are fully vested and exercisable.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| December 18, 2024 Filed Dec 19, 2024 18:57 UTC | Xenon Pharmaceuticals Inc. XENE · Entity 2602 | Exercise / conversionStock Option (Right to Buy) · Derivative | 16,000 | $0.00 Strike: $11.58 | $0.00 |
DisclosureSEC source: 0000950170-24-138629 · ownership.xml · derivative · entry 8 AULIN SHERRY · CIK 0001862144 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 6,000 Underlying: Common Shares · 16,000 shares Expires 2030-03-11 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: The shares subject to the option are fully vested and exercisable. Read SEC document |
| December 18, 2024 Filed Dec 19, 2024 18:57 UTC | Xenon Pharmaceuticals Inc. XENE · Entity 2602 | Exercise / conversionStock Option (Right to Buy) · Derivative | 9,334 | $0.00 Strike: $9.44 | $0.00 |
DisclosureSEC source: 0000950170-24-138629 · ownership.xml · derivative · entry 7 AULIN SHERRY · CIK 0001862144 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Shares · 9,334 shares Expires 2029-09-15 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: The shares subject to the option are fully vested and exercisable. Read SEC document |
| December 18, 2024 Filed Dec 19, 2024 18:57 UTC | Xenon Pharmaceuticals Inc. XENE · Entity 2602 | SaleCommon Shares | 11,510 | $41.19 | $474,096.90 |
DisclosureSEC source: 0000950170-24-138629 · ownership.xml · nonDerivative · entry 6 AULIN SHERRY · CIK 0001862144 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 F2 · price: The "Amount" and "Price" reported in this Column 4 reflect the aggregate number and weighted-average price, respectively, of shares sold. These shares were sold in multiple transactions at prices ranging from $41.19 to $41.20, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, full information regarding the number of shares sold at each separate price within the range set forth herein. Read SEC document |
| December 18, 2024 Filed Dec 19, 2024 18:57 UTC | Xenon Pharmaceuticals Inc. XENE · Entity 2602 | Tax withholdingCommon Shares | 4,490 | $41.28 | $185,347.20 |
DisclosureSEC source: 0000950170-24-138629 · ownership.xml · nonDerivative · entry 5 AULIN SHERRY · CIK 0001862144 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 11,510 F1 · price: Represents the closing price of the Company's common shares on December 17, 2024 for purposes of net settlement calculations. Read SEC document |
| December 18, 2024 Filed Dec 19, 2024 18:57 UTC | Xenon Pharmaceuticals Inc. XENE · Entity 2602 | Exercise / conversionCommon Shares | 16,000 | $11.58 | $185,280.00 |
DisclosureSEC source: 0000950170-24-138629 · ownership.xml · nonDerivative · entry 4 AULIN SHERRY · CIK 0001862144 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 16,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| December 18, 2024 Filed Dec 19, 2024 18:57 UTC | Xenon Pharmaceuticals Inc. XENE · Entity 2602 | SaleCommon Shares | 7,199 | $41.23 | $296,814.77 |
DisclosureSEC source: 0000950170-24-138629 · ownership.xml · nonDerivative · entry 3 AULIN SHERRY · CIK 0001862144 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Read SEC document |
| December 18, 2024 Filed Dec 19, 2024 18:57 UTC | Xenon Pharmaceuticals Inc. XENE · Entity 2602 | Tax withholdingCommon Shares | 2,135 | $41.28 | $88,132.80 |
DisclosureSEC source: 0000950170-24-138629 · ownership.xml · nonDerivative · entry 2 AULIN SHERRY · CIK 0001862144 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 7,199 F1 · price: Represents the closing price of the Company's common shares on December 17, 2024 for purposes of net settlement calculations. Read SEC document |
| December 18, 2024 Filed Dec 19, 2024 18:57 UTC | Xenon Pharmaceuticals Inc. XENE · Entity 2602 | Exercise / conversionCommon Shares | 9,334 | $9.44 | $88,112.96 |
DisclosureSEC source: 0000950170-24-138629 · ownership.xml · nonDerivative · entry 1 AULIN SHERRY · CIK 0001862144 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 9,334 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 11, 2024 Filed Mar 12, 2024 18:41 UTC | Xenon Pharmaceuticals Inc. XENE · Entity 2602 | GrantStock Option (Right to Buy) · Derivative | 100,000 | $0.00 Strike: $44.37 | $0.00 |
DisclosureSEC source: 0000950170-24-030245 · ownership.xml · derivative · entry 1 AULIN SHERRY · CIK 0001862144 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 100,000 Underlying: Common Shares · 100,000 shares Expires 2034-03-10 F1 · derivative.exercise_date: Vesting 25% on January 1, 2025, and 75% vesting thereafter over the course of the next 3 years, in equal amounts, on the last day of each month. Read SEC document |
| March 10, 2023 Filed Mar 14, 2023 16:25 UTC | Xenon Pharmaceuticals Inc. XENE · Entity 2602 | GrantStock Option (Right to Buy) · Derivative | 120,000 | $0.00 Strike: $34.18 | $0.00 |
DisclosureSEC source: 0001209191-23-018467 · doc4.xml · derivative · entry 1 AULIN SHERRY · CIK 0001862144 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 120,000 Underlying: Common Shares · 120,000 shares Expires 2033-03-09 F1 · derivative.exercise_date: Vesting 25% on January 1, 2024 and 75% vesting thereafter over the course of the next 3 years, in equal amounts, on the last day of each month. Read SEC document |
| September 02, 2022 Filed Sep 7, 2022 16:26 UTC | Xenon Pharmaceuticals Inc. XENE · Entity 2602 | Exercise / conversionStock Option (Right to Buy) · Derivative | 6,511 | $0.00 Strike: $4.75 | $0.00 |
DisclosureSEC source: 0001209191-22-049015 · doc4.xml · derivative · entry 12 AULIN SHERRY · CIK 0001862144 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Shares · 6,511 shares Expires 2028-03-11 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: The shares subject to the option are fully vested and exercisable. Read SEC document |
| September 02, 2022 Filed Sep 7, 2022 16:26 UTC | Xenon Pharmaceuticals Inc. XENE · Entity 2602 | Exercise / conversionStock Option (Right to Buy) · Derivative | 2,292 | $0.00 Strike: $3.10 | $0.00 |
DisclosureSEC source: 0001209191-22-049015 · doc4.xml · derivative · entry 11 AULIN SHERRY · CIK 0001862144 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Shares · 2,292 shares Expires 2027-10-22 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: The shares subject to the option are fully vested and exercisable. Read SEC document |
| September 02, 2022 Filed Sep 7, 2022 16:26 UTC | Xenon Pharmaceuticals Inc. XENE · Entity 2602 | Exercise / conversionStock Option (Right to Buy) · Derivative | 813 | $0.00 Strike: $8.40 | $0.00 |
DisclosureSEC source: 0001209191-22-049015 · doc4.xml · derivative · entry 10 AULIN SHERRY · CIK 0001862144 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Shares · 813 shares Expires 2027-03-12 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: The shares subject to the option are fully vested and exercisable. Read SEC document |
| September 02, 2022 Filed Sep 7, 2022 16:26 UTC | Xenon Pharmaceuticals Inc. XENE · Entity 2602 | Exercise / conversionStock Option (Right to Buy) · Derivative | 32 | $0.00 Strike: $7.49 | $0.00 |
DisclosureSEC source: 0001209191-22-049015 · doc4.xml · derivative · entry 9 AULIN SHERRY · CIK 0001862144 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Shares · 32 shares Expires 2026-03-10 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: The shares subject to the option are fully vested and exercisable. Read SEC document |
| September 02, 2022 Filed Sep 7, 2022 16:26 UTC | Xenon Pharmaceuticals Inc. XENE · Entity 2602 | Exercise / conversionStock Option (Right to Buy) · Derivative | 9,000 | $0.00 Strike: $9.44 | $0.00 |
DisclosureSEC source: 0001209191-22-049015 · doc4.xml · derivative · entry 8 AULIN SHERRY · CIK 0001862144 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Shares · 9,000 shares Expires 2029-09-15 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: The shares subject to the option are fully vested and exercisable. Read SEC document |
| September 02, 2022 Filed Sep 7, 2022 16:26 UTC | Xenon Pharmaceuticals Inc. XENE · Entity 2602 | SaleCommon Shares | 15,355 | $39.57 | $607,597.35 |
DisclosureSEC source: 0001209191-22-049015 · doc4.xml · nonDerivative · entry 7 AULIN SHERRY · CIK 0001862144 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F2 · price: The "Amount" and "Price" reported in this Column 4 reflect the aggregate number and weighted-average price, respectively, of shares sold. These shares were sold in multiple transactions at prices ranging from $39.50 to $39.63, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, full information regarding the number of shares sold at each separate price within the range set forth herein. Read SEC document |
| September 02, 2022 Filed Sep 7, 2022 16:26 UTC | Xenon Pharmaceuticals Inc. XENE · Entity 2602 | Tax withholdingCommon Shares | 3,293 | $39.53 | $130,172.29 |
DisclosureSEC source: 0001209191-22-049015 · doc4.xml · nonDerivative · entry 6 AULIN SHERRY · CIK 0001862144 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,355 F1 · price: Represents the closing price of the Company's common shares on September 1, 2022 for purposes of net settlement calculations. Read SEC document |
| September 02, 2022 Filed Sep 7, 2022 16:26 UTC | Xenon Pharmaceuticals Inc. XENE · Entity 2602 | Exercise / conversionCommon Shares | 6,511 | $4.75 | $30,927.25 |
DisclosureSEC source: 0001209191-22-049015 · doc4.xml · nonDerivative · entry 5 AULIN SHERRY · CIK 0001862144 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,648 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| September 02, 2022 Filed Sep 7, 2022 16:26 UTC | Xenon Pharmaceuticals Inc. XENE · Entity 2602 | Exercise / conversionCommon Shares | 2,292 | $3.10 | $7,105.20 |
DisclosureSEC source: 0001209191-22-049015 · doc4.xml · nonDerivative · entry 4 AULIN SHERRY · CIK 0001862144 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,137 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| September 02, 2022 Filed Sep 7, 2022 16:26 UTC | Xenon Pharmaceuticals Inc. XENE · Entity 2602 | Exercise / conversionCommon Shares | 813 | $8.40 | $6,829.20 |
DisclosureSEC source: 0001209191-22-049015 · doc4.xml · nonDerivative · entry 3 AULIN SHERRY · CIK 0001862144 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,845 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| September 02, 2022 Filed Sep 7, 2022 16:26 UTC | Xenon Pharmaceuticals Inc. XENE · Entity 2602 | Exercise / conversionCommon Shares | 32 | $7.49 | $239.68 |
DisclosureSEC source: 0001209191-22-049015 · doc4.xml · nonDerivative · entry 2 AULIN SHERRY · CIK 0001862144 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,032 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| September 02, 2022 Filed Sep 7, 2022 16:26 UTC | Xenon Pharmaceuticals Inc. XENE · Entity 2602 | Exercise / conversionCommon Shares | 9,000 | $9.44 | $84,960.00 |
DisclosureSEC source: 0001209191-22-049015 · doc4.xml · nonDerivative · entry 1 AULIN SHERRY · CIK 0001862144 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 10, 2022 Filed Mar 14, 2022 16:11 UTC | Xenon Pharmaceuticals Inc. XENE · Entity 2602 | GrantStock Option (Right to Buy) · Derivative | 125,000 | $0.00 Strike: $30.01 | $0.00 |
DisclosureSEC source: 0001209191-22-018445 · doc4.xml · derivative · entry 1 AULIN SHERRY · CIK 0001862144 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 125,000 Underlying: Common Shares · 125,000 shares Expires 2032-03-09 F1 · derivative.exercise_date: Vesting 25% on January 1, 2023 and 75% vesting thereafter over the course of the next 3 years, in equal amounts, on the last day of each month. Read SEC document |
| June 03, 2021 Filed Jun 3, 2021 16:42 UTC | Xenon Pharmaceuticals Inc. XENE · Entity 2602 | GrantStock Option (Right to Buy) · Derivative | 100,000 | $0.00 Strike: $18.56 | $0.00 |
DisclosureSEC source: 0001209191-21-037692 · doc4.xml · derivative · entry 1 AULIN SHERRY · CIK 0001862144 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 100,000 Underlying: Common Shares · 100,000 shares Expires 2031-06-02 F1 · derivative.exercise_date: Vesting 25% on the one year anniversary of the grant date, and 75% vesting thereafter over the course of the next 3 years, in equal amounts, on the last day of each month. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.